University of North Carolina School of Law and University of North Carolina School of Medicine, Chapel Hill, NC.
Chest. 2014 Feb;145(2):379-385. doi: 10.1378/chest.13-1719.
Under brand new rules implementing the Physician Payments Sunshine Act (Sunshine Act), a wide range of financial relationships, including many research-related payments, between industry, physicians, and teaching hospitals will be publicly disclosed through comprehensive, standardized payment reporting. The Sunshine Act represents the latest in a series of regulatory attempts to address financial conflicts of interest that may bias research conduct and threaten subject safety. This article summarizes the major aspects of the Sunshine Act affecting medical research, how it interacts with existing laws and policies, and identifies important unresolved issues and implementation challenges that still lie ahead with the rollout of the legislation underway. The Sunshine Act primarily depends on disclosure as a regulatory tool. As such, its long-term impact remains open to question. Disclosure in this context may have limited utility given, among other reasons, uncertainty about who the intended recipients are and their ability to use the information effectively. Apart from the insufficiency of transparency, this article further explores how proportionality, fairness, and accountability considerations make optimal regulation of financial conflicts in medical research quite challenging.
根据实施《医师阳光法案》(Sunshine Act)的全新规定,将通过全面、标准化的支付报告,公开披露制药业、医生和教学医院之间的各种财务关系,包括许多与研究相关的付款。《阳光法案》是一系列旨在解决可能影响研究行为和威胁研究对象安全的财务利益冲突的监管措施中的最新举措。本文总结了《阳光法案》中影响医学研究的主要方面,以及它与现有法律和政策的相互作用,并确定了立法实施过程中仍然存在的重要未决问题和实施挑战。《阳光法案》主要依赖于信息披露作为监管工具。因此,其长期影响仍有待观察。在这种情况下,披露的作用有限,原因之一是,人们不确定信息的预期接收者是谁,以及他们是否有能力有效利用这些信息。除了透明度不足之外,本文还进一步探讨了相称性、公平性和问责制考虑因素如何使得对医学研究中的财务利益冲突进行最佳监管颇具挑战性。